BioCryst Pharmaceuticals Investor Relations Material
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company offers peramivir, an intravenous neuraminidase inhibitor, which completed Phase III clinical trial for the treatment of acute uncomplicated influenza in hospitalized adult and pediatric patients in Japan; BCX4161, an oral purine nucleoside phosphorylase (PNP) inhibitor for the treatment of hereditary angioedema; galidesivir, a broad spectrum viral RNA polymerase inhibitor that is under pre-clinical development against various high priority viruses associated with biodefense threat; and BCX9250 that is under pre-clinical development for the treatment of gout.
Key slides for BioCryst Pharmaceuticals Inc
NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023
The Story of Jensen Huang and Nvidia
When looking at NVIDIA’s Jensen Huang today, it is easy to stereotype him as your archetypical big tech CEO. He doesn’t wear suits like a Wall Street Chairman, instead opting to wear his now-iconic leather jackets and casual polo shirts.
6 Dec 2023
Neglect of Probability: A Hidden Risk in Decision Making
The concept of "probability" should take center stage in our decision-making processes.
4 Dec 2023
🇺🇸 United States